Lyomark Pharma GmbH

About Lyomark Pharma GmbH

Lyomark is specialised in niche proprietary and generic products and orphan drugs for rare diseases, presented as sterile injectable, lyophilized formulations in pre-filled syringes, vials and ampoule's. Lyomark is active in the area of respiratory disease, oncology, metabolism etc.

  • DE
  • 2015
    On CPHI since
Company types
Distributor/Import Export
Licensee
Contact info

Products from Lyomark Pharma GmbH (3)

  • Alveofact® - Natural bovine lung surfactant

    Product Alveofact® - Natural bovine lung surfactant

    Alveofact is used in neonates. Preventive use in premature neonates with a high risk of respiratory distress syndrome (RDS).
    Active substance: Phospholipid fractionfrom bovine lung (surfactant)
  • Neofact® - Medical device for surfactant application

    Product Neofact® - Medical device for surfactant application

    Neofact is an innovative applicator for instillation of surfactant and is used for the management of respiratory distress syndrome (RDS) in preterm and term neonates:

    • Simple and practical handling • Application of surfactant without Magill forceps • Precise positioning in ...
  • Neofact - Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)

    Product Neofact - Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)

    Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
    This study shows that the LISA method (less invasive surfactant administration) via Neofact® appears feasible. 

    Neofact® makes surfactant application easy and is also suitable for all gesta...

Lyomark Pharma GmbH Resources (2)

  • News Neofact - Clinical evaluation of an applicator for surfactant administration

    Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
    This study shows that the LISA method (less invasive administration) via Neofact® appears feasible. 

    Neofact® makes surfactant application easy and can also be used at any gestational age.

    https://pubmed.ncbi.nlm.nih.gov/33023914/
  • Technical Data Neofact® - Feasibility study

    In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

    Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/